Chai Discovery announced it has raised $70 million in Series A funding led by Menlo Ventures, with participation from Yosemite, DST Global Partners, SV Angel, Avenir, DCVC and others. Several existing investors, including Thrive Capital, OpenAI and Dimension, also joined the round. The raise brings the company’s total funding to $100 million.
Founded in 2024, Chai Discovery uses AI to predict and reprogram interactions between biochemical molecules, aiming to accelerate drug discovery and other therapeutic developments. The company recently released its Chai-2 model, which can design fully de novo antibodies with a near-20 percent hit rate, significantly outperforming previous computational methods.
The company plans to use the funding to enhance its platform, target previously inaccessible molecules and onboard select partners in the biotech sector. Former Pfizer Chief Scientific Officer Mikael Dolsten has also joined Chai Discovery’s board.
